NetworkNewsBreaks – Grey Cloak Tech Inc. (GRCK)
Post# of 121
(Total Views: 482)
Posted On: 12/15/2020 4:10:12 PM
NetworkNewsBreaks – Grey Cloak Tech Inc. (GRCK) Subsidiary Enters Strategic Agreement with Key Account
Grey Cloak Tech (OTCQB: GRCK) (soon to be Healthy Extracts Inc.), a company engaged in proprietary development of natural plant-based formulations and sales and distribution of cardiovascular and neuro products, today announced that its subsidiary BergaMet NA has entered into an exclusive performance-driven agreement with Xymogen(R) to purchase BergaMet’s Citrus Bergamot SuperFruit(TM). According to the update, the agreement has been three years in development, and Xymogen is now selling and distributing proprietary formulations of BergaCor(TM) and BergaCorPlus(TM) to its 20,000- plus medical doctor network. “This partnership with Xymogen exemplifies Bergamet NA’s strategic B2B goal of a continued growth strategy,” said Duke Pitts, president of BergaMet NA. “We are very excited as this agreement provides significant revenue generation and distribution through Xymogen’s national market footprint. Xymogen also sells our recently introduced CLINICAL IMMUNE(TM) and we anticipate introducing new products as they become available.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Grey Cloak Tech (OTCQB: GRCK) (soon to be Healthy Extracts Inc.), a company engaged in proprietary development of natural plant-based formulations and sales and distribution of cardiovascular and neuro products, today announced that its subsidiary BergaMet NA has entered into an exclusive performance-driven agreement with Xymogen(R) to purchase BergaMet’s Citrus Bergamot SuperFruit(TM). According to the update, the agreement has been three years in development, and Xymogen is now selling and distributing proprietary formulations of BergaCor(TM) and BergaCorPlus(TM) to its 20,000- plus medical doctor network. “This partnership with Xymogen exemplifies Bergamet NA’s strategic B2B goal of a continued growth strategy,” said Duke Pitts, president of BergaMet NA. “We are very excited as this agreement provides significant revenue generation and distribution through Xymogen’s national market footprint. Xymogen also sells our recently introduced CLINICAL IMMUNE(TM) and we anticipate introducing new products as they become available.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Healthy Extracts Inc. (HYEX) Stock Research Links
Scroll down for more posts ▼